Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Modification of tumor regression by immunologic means.

× No keyword cloud information.

18 in total

1. Combination chemotherapy.

Authors: T A Connors
Journal: Proc R Soc Med Date: 1974-06

Review 2. Adapting conventional cancer treatment for immunotherapy.

Authors: Jian Qiao; Zhida Liu; Yang-Xin Fu
Journal: J Mol Med (Berl) Date: 2016-02-24 Impact factor: 4.599

3. Attempt to alter antigenic structure of normal tissues by treatment with dimethyl-triazeno-imidazole-carboxamide in vivo.

Authors: A Nicolin; R Fagnani; G Nicolotti; A Goldin
Journal: Experientia Date: 1976-06-15

4. Chronic chemoimmunotherapy achieves cure of spontaneous murine mammary tumors via persistent blockade of posttherapy counter-regulation.

Authors: Rachael B Rowswell-Turner; Jamie L Harden; Raji E Nair; Tao Gu; Mehmet O Kilinc; Nejat K Egilmez
Journal: J Immunol Date: 2011-09-09 Impact factor: 5.422

5. Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.

Authors: L M Weiskirch; E Barker; M B Mokyr
Journal: Cancer Immunol Immunother Date: 1990 Impact factor: 6.968

6. Adoptive immunity in mice challenged with L1210/DTIC clones.

Authors: G Canti; L Ricci; O Marelli; P Franco; A Nicolin
Journal: Cancer Immunol Immunother Date: 1987 Impact factor: 6.968

Review 7. Tumor progression in metastasis: an experimental approach using lectin resistant tumor variants.

Authors: R S Kerbel; J W Dennis; A E Largarde; P Frost
Journal: Cancer Metastasis Rev Date: 1982 Impact factor: 9.264

Review 8. Chemical xenogenization of experimental tumors.

Authors: P Puccetti; L Romani; M C Fioretti
Journal: Cancer Metastasis Rev Date: 1987 Impact factor: 9.264

Review 9. Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer.

Authors: Tianqian Zhang; Dorothee Herlyn
Journal: Cancer Immunol Immunother Date: 2008-10-17 Impact factor: 6.968

10. Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers.

Authors: L M Weiskirch; B A Baumgartel; E Barker; M B Mokyr
Journal: Cancer Immunol Immunother Date: 1991 Impact factor: 6.968